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ABSTRACT Efﬁcientvaccinationagainstinfectiousagentsandtumorsdependsonspeciﬁcantigentargetingtodendriticcells
(DCs).Wereportherethatbiosafecoronavirus-basedvaccinevectorsfacilitatedeliveryofmultipleantigensandimmunostimu-
latory cytokines to professional antigen-presenting cells in vitro and in vivo. Vaccine vectors based on heavily attenuated mu-
rinecoronavirusgenomesweregeneratedtoexpressepitopesfromthelymphocyticchoriomeningitisvirusglycoprotein,orhu-
manMelan-A,incombinationwiththeimmunostimulatorycytokinegranulocyte-macrophagecolony-stimulatingfactor(GM-
CSF). These vectors selectively targeted DCs in vitro and in vivo resulting in vector-mediated antigen expression and efﬁcient
maturationofDCs.Singleapplicationofonlylowvectordoseselicitedstrongandlong-lastingcytotoxicT-cellresponses,pro-
vidingprotectiveantiviralandantitumorimmunity.Furthermore,humanDCstransducedwithMelan-A-recombinanthuman
coronavirus229Eefﬁcientlyactivatedtumor-speciﬁcCD8Tcells.Takentogether,thisnovelvaccineplatformiswellsuitedto
deliverantigensandimmunostimulatorycytokinestoDCsandtoinitiateandmaintainprotectiveimmunity.
IMPORTANCE Vaccinationagainstinfectiousagentshasprotectedmanyindividualsfromseveredisease.Inaddition,prophylacticand,
mostlikely,alsotherapeuticvaccinationagainsttumorswillsavemillionsfrommetastaticdisease.Thisstudydescribesanovelvaccine
approachthatfacilitatesdeliveryofviralortumorantigenstodendriticcellsinvivo.Concomitantimmunostimulationviathecyto-
kinegranulocyte-macrophagecolony-stimulatingfactor(GM-CSF)wasachievedthroughdeliverybythesameviralvector.Singleim-
munizationwithonlylowdosesofcoronavirus-basedvaccinevectorswassufﬁcienttoelicit(i)vigorousexpansionandoptimaldiffer-
entiationofCD8Tcells,(ii)protectiveandlong-lastingantiviralimmunity,and(iii)prophylacticandtherapeutictumorimmunity.
Moreover,highlyefﬁcientantigendeliverytohumanDCswithrecombinanthumancoronavirus229Eandspeciﬁcstimulationofhu-
manCD8Tcellsrevealedthatthisapproachisexceptionallywellsuitedfortranslationintohumanvaccinestudies.
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V
accination against viral infections has saved millions of lives by
protecting many individuals from diseases such as measles, ru-
bella, mumps, and polio. However, there is a growing need not only
todevelopimprovedvaccinesagainstsuchacuteinfectionsbutalsoto
generate therapeutic vaccines which can stimulate speciﬁc immune
responsestopersistentvirusessuchasthehumanimmunodeﬁciency
virus or the human hepatitis C virus (1, 2). Likewise, novel ap-
proachesforvaccinationagainsttumorswhichcounteracttheimmu-
nosuppression associated with cancer are needed (3). There is com-
pellingevidencethatCD8cytotoxicTcellsarecrucialplayersinthe
protective immune response against viral infections and tumors (4).
Novel vaccine approaches should thus be rigorously evaluated for
their ability to maximally expand antigen-speciﬁc CD8 T cells, to
inducetheiroptimaldifferentiationintoeffectorCD8Tcells,andto
elicit long-lasting protective memory (4).
A major bottleneck in the development of new and effective
vaccines is the delivery of antigens to dendritic cells (DCs) (5, 6),
which sample the antigen, transport immunogenic components
to secondary lymphoid organs, and initiate and maintain T and B
cell responses. The excellent capacity of DCs to prime protective
antiviral T cell responses has been shown in vivo (7–9). Likewise,
several preclinical studies demonstrated that efﬁcient antitumor
immunitycanbeinducedusingadoptivetransferofDCs(10–12).
Although individualized adoptive transfer of antigen-loaded DCs
is feasible and, to a certain extent, efﬁcient in clinical applications
to humans (13), off-the-shelf vaccines that permit targeted deliv-
ery of antigens to DCs in vivo have become a major focus in vac-
cine development. Consequently, the description of cell surface
moleculesthat,forexample,exhibitaratherspeciﬁcexpressionby
DCs has fueled the development of antibody-based targeting
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T cell and B cell responses against a range of different antigens.
However, antigen coupling to antibodies is a major limitation
for the induction of CD8 T cell responses which are strictly
dependent on cross-presentation (5, 17). In contrast, viral vec-
tors encoding immunogenic antigens can deliver their genetic
cargo directly into DCs, thus generating antigenic peptides in
infected cells and allowing for efﬁcient loading of major histo-
compatibility complex (MHC) class I molecules. Among the
currently most exploited virus systems that facilitate antigen
delivery to DCs are adenoviral (18, 19), lentiviral (20), arena-
viral (21), and alphaviral (22, 23) systems. However, major
impediments of these vectors are frequent off-target transduc-
tion, resulting in antigen presentation by parenchymal cells
outside secondary lymphoid organs, and limited cloning ca-
pacityfortheinsertionofmultipleorlargeantigens.Forexam-
ple, the strong tropism of adenoviral vectors for hepatocytes,
with 95% of the genetic material being deposited in the liver,
leads to generation of functionally impaired CD8 T cells (24,
25).Majoreffortsarethusrequiredtoengineeradenoviralvec-
tors with improved speciﬁcity for the relevant antigen-
presenting cells (12, 19). Likewise, lentiviral vectors preferen-
tiallyinfectcellsotherthanDCs,andredirectionoftheirtarget
cell tropism is warranted (26). An additional potential imped-
FIG1 Generation,propagation,andinvitrotargetcelltropismofMHV-basedvaccinevectors.(A)SchematicrepresentationoftheMHV-A59genomeandthe
highly attenuated MHV vectors. (B) Packaging concept for the generation of replication-competent but propagation-deﬁcient MHV particles. (C) Growth
kineticsoftheindicatedMHVvectorsin17ECl20packagingcells.CellswereinfectedatanMOIof1,andtitersinsupernatantsweredeterminedattheindicated
timepoints(meansofresultsfromtriplicatemeasurementsstandarderrorsofthemeans[SEM]).(D)ReplicationoftheindicatedMHVvectorsorMHV-A59
wild-typevirusinL929cells,bonemarrow-derivedDCs,andperitonealmacrophages.Theindicatedcells(106/ml,MOI1)wereinfected,andreplicationwas
monitored by titration of supernatants on 17ECl20 packaging cells (mean  SEM of duplicate measurements). One representative experiment out of three is
displayed. (E) Transduction of L929 cells and peritoneal macrophages with an MHV-GP or MHV-GM/GP vector (MOI  1). Green ﬂuorescence was recorded
6 h posttransduction. Original magniﬁcation, 400. (F, G) Stimulation of DCs by GM-CSF-expressing vectors. Bone marrow-derived DCs (106) from B6 mice
were transduced with the indicated MHV-based vector (MOI  1) or left untreated. Cells were harvested 12 h later and stained for CD11c, CD86, and CD40
expression. (F) Representative dot plots indicating the high transduction efﬁcacy. Values in the upper right quadrant indicate percentages of EGFP cells. (G)
ExpressionoftheDCactivationmarkersCD86andCD40onuntreatedCD11ccells(shaded),onCD11cEGFPcells(thickblackline),oronCD11cEGFP
cells (thick red line). Values in the histograms represent mean ﬂuorescence intensity of the respective population.
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their potential to integrate genomic material into the host
genome (27).
Coronaviralvectorsdisplayanumberoffeaturesthatclearlyover-
come these limitations. First, replication of these positive-stranded
RNA viruses is restricted to the cytoplasm, without a DNA interme-
diary, making insertion of viral sequences into the host cell genome
unlikely. Second, there is accumulating knowledge on how to atten-
uatecoronavirusesinordertoprovidebiosafevectors(28,29).Third,
coronavirus genomes with sizes of 27 to 31 kb represent the largest
autonomouslyreplicatingRNAsknowntodateandthusofferaclon-
ingcapacityofmorethan6kb.Fourth,theuniquetranscriptionpro-
cess generates 6 to 8 subgenomic mRNAs encoding the four canoni-
cal structural proteins and various numbers of accessory proteins,
whichcanbereplacedtoencodemultipleheterologousproteins(30).
Finally,andcertainlymostintriguing,cellsurfacereceptorsofhuman
andmurinecoronavirusesareexpressedonhumanandmurineDCs,
respectively (31, 32).
The present study describes the generation and evaluation of
rationally designed coronavirus-based vectors that efﬁciently tar-
getantigensandimmunostimulatorymoleculestoDCs.Weshow
that murine-coronavirus-based vectors can deliver multiple
antigens and immunostimulatory cytokines almost exclusively
to CD11c DCs within secondary lymphoid organs. Immuni-
zationwithonlylownumbersofparticleselicitedpotentCD8
T cell responses that provided long-lasting protection against
viral challenge. Moreover, single appli-
cation of these novel viral vectors gen-
erated prophylactic and therapeutic im-
munity against metastatic melanoma.
Induction of cytotoxic T lymphocytes
(CTL) directed against the human
Melan-A (Mel-A) antigen in HLA-A2-
transgenic mice and efﬁcient human-
DC-mediated stimulation of Mel-A-
speciﬁc CTL through Mel-A-
recombinant human coronavirus 229E
(HCoV-229E) indicates that
coronavirus-mediated gene transfer to
DCs represents a versatile approach for
murine and human immunization
against both viral infection and cancer.
RESULTS
Design and propagation of biosafe
coronavirus-based vaccine vectors. To
assess immunogenicity and to ensure
maximal safety of coronavirus-based
multigene vaccine vectors, we have ratio-
nally designed a series of prototype vec-
tors based on the mouse hepatitis virus
strain A59 (MHV-A59) (Fig. 1A). With
regard to safety, we introduced three ba-
sic modiﬁcations to obtain replication-
competent, but attenuated and
propagation-deﬁcient, MHV-based vec-
tors. First, we deleted all MHV accessory
genes(NS2,HE,gene4,gene5a),astrategy
that attenuates MHV in the natural host
(29) and provides space for the introduc-
tion of heterologous genes. Second, we
removed 99 nucleotides within the replicase gene-encoded se-
quence of nonstructural protein 1 (nsp1), because this deletion
has been shown to greatly reduce MHV pathogenicity while re-
tainingimmunogenicity(28).Finally,wedeletedstructuralgeneE
to restrict proper particle formation (33). Indeed, although repli-
cationofwild-typeMHVtomaximaltitersoccurredaroundday5
postinfection, in vivo replication of MHV vectors could not be
detected(notshown).Consequently,therewasalsonoMHVvec-
torreplicationdetectableinliversorbrains(notshown).Thehigh
safety proﬁle of MHV-based vectors is further illustrated by the
fact that the health status of C57BL/6 (B6) or different immuno-
deﬁcient mice was not affected, even if the vectors were applied at
high doses (see Fig. S1 in the supplemental material).
In order to test the coronavirus-based vaccine concept and to
develop a vaccine that provides strong CTL responses, in terms of
both magnitude and longevity, we used the CTL epitope gp33-41
(theregionfromresidues33to41),derivedfromthelymphocytic
choriomeningitis virus (LCMV) glycoprotein, and the Mel-A26-35
analog peptide, derived from the human Melan-A/melanoma an-
tigenrecognizedbyTcells1(MART1)protein(Fig.1A).TheCTL
epitopes were cloned as fusion proteins with the enhanced green
ﬂuorescentprotein(EGFP)(34,35),andthecorrespondinggenes,
designated GP-EGFP and EGFP–Mel-A, were cloned between the
MHVvector-bornespikeandmembranegenes.Sinceappropriate
stimulation of DCs is critical for the generation of efﬁcient T cell
FIG 2 In vivo antigen delivery to dendritic cells by MHV-based vaccine vectors. B6 mice were immu-
nized i.v. with 106 PFU MHV-GP or MHV-GM/GP or were left untreated. Spleens were collected after
18 h, 24 h, or 36 h and digested with collagenase, and low-density cells were isolated by gradient
centrifugation.ExpressionofCD11c,CD11b,CD8,CD86,andCD40onDCswasdeterminedbyﬂow
cytometry.(A)TimecourseanalysisofEGFPexpressioninCD11cDCs.Pooleddatafromtwoseparate
experiments(5micepertimepoint).Valuesintheupperrightquadrantindicatemeanpercentagesplus
SEM of EGFP cells. (B) Expression of CD11b and CD8 in transduced DCs at 18 h postinfection.
Values in the quadrants represent percentages of CD11b or CD8 cells in the EGFP CD11c DCs.
(C) DC activation assessed as CD86 and CD40 upregulation on EGFP CD11c and EGFP CD11c
cells at the 18-h time point. Values in the histograms represent mean ﬂuorescence intensity of the
respective population. PBS, phosphate-buffered saline.
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nallydesignedvaccines,weinsertedthegeneencodingthemurine
granulocyte-macrophage colony-stimulating factor (GM-CSF)
between the MHV vector-borne replicase and spike genes
(Fig. 1A). To propagate the MHV-based viral vectors to high ti-
ters, we produced a packaging cell line based on murine 17clone1
cellsthatexpresstheMHVenvelope(E)proteinunderthecontrol
of the Tet-off system (Fig. 1B). This strategy enabled us to restore
efﬁcient vector particle formation and propagation in order to
obtain vector stocks of 106/ml (Fig. 1C).
DC-speciﬁcdeliveryofcoronavirusvector-encodedantigens
andcytokines.ToassessMHVvectorgrowthkineticsoncellsthat
do not express the E protein, we transduced L929 cells, bone
marrow-derivedCD11cDCs,orperito-
neal macrophages with the MHV vectors
and compared growth kinetics to that of
wild-type MHV-A59. In accordance with
reports on E gene-deﬁcient MHV-A59
(37), the growth of the MHV-based vec-
tor was greatly impaired in L929 cells
(Fig. 1D). Most importantly, however,
MHV vector transduction did not result
in particle release in peritoneal macro-
phages and DCs, demonstrating that the
lackoftheEproteinpreventsMHVprop-
agation in primary cells (Fig. 1D). MHV
vectors elicited signiﬁcant EGFP expres-
sion in transduced L929 cells and perito-
neal macrophages (Fig. 1E) and in
CD11c DCs (Fig. 1F). Notably, vector-
mediatedGM-CSFexpressionresultedin
DC activation and maturation, as shown
by upregulation of CD86 and CD40 on
CD11c cells (Fig. 1G). The rapid pro-
duction of GM-CSF in L929 cells, perito-
nealmacrophages,andDCsfollowingex-
posure to the cytokine-encoding vectors
(Fig. S2) shows that MHV vectors can be
used to simultaneously express antigens
andimmunostimulatorycytokinesintar-
get cells.
To further determine the cellular tro-
pism of MHV-based vectors, we trans-
duced splenocytes from C57BL/6 (B6)
mice with MHV-GM/GP in vitro and an-
alyzed EGFP expression by ﬂow cytom-
etry. Neither CD4 nor CD8 T cells
were susceptible to MHV-GM/GP trans-
duction (not shown), whereas antigen-
presenting cells, such as B cells (CD19),
macrophages (F4/80 or CD11b), and
DCs (CD11C), displayed green ﬂuores-
cence indicative of MHV vector-
mediated EGFP expression (see Fig. S3A
inthesupplementalmaterial).Inorderto
evaluate whether targeting of DCs and
macrophagesisalsoachievableinvivo,we
injected (intravenously [i.v.]) 106 PFU of
MHV-GPorMHV-GM/GPintoB6mice
andanalyzedEGFPexpressionofspleno-
cytes by ﬂow cytometry. EGFP expression was detectable mainly
in CD11c CD11b DCs and CD11c CD8 DCs (Fig. 2A and
B and see Fig. S3B in the supplemental material). Finally, we as-
sessed the effects of MHV vector-mediated GM-CSF expression
on DC stimulation and activation in vivo. Slightly elevated GM-
CSF levels in spleens could be observed following application of
the MHV-GM/GP vector (Fig. S4A), whereas GM-CSF levels in
serum remained below the limit of detection (not shown). Con-
comitant immunization with MHV-GP and MHV-GM/Mel-A
vectors revealed that the supply of GM-CSF in trans, i.e., via the
MHV-GM/Mel-A vector was not sufﬁcient to achieve the maxi-
malactivationofgp34-speciﬁcCD8Tcells.OnlywhenGM-CSF
wasencodedbythesamevectorthatexpressedtheGP-EGFPpro-
FIG3 Evaluation of antiviral CD8 T cell responses. (A) B6 mice were immunized i.v. with either 200
PFULCMV,105PFUMHV-GP,or105PFUMHV-GM/GP.Splenocyteswereanalyzedonday7postin-
fection (p.i.) for expression of CD8 and reactivity with H2-Db/gp33 or H2-Kb/gp34 tetramers, and
CD8 splenocytes were analyzed for gp33- and gp34-speciﬁc IFN- production. Values in the upper
right quadrants represent percentages of Tet cells  SEM (upper row) or percentages of IFN- cells
 SEM (lower row) in the CD8 T-cell compartment (mean  SEM; 3 mice per group). (B, C) Efﬁcacy
of MHV-based vectors in inducing antiviral CD8 T cell responses. B6 mice were immunized i.v. with
theindicateddosesofMHV-GPorMHV-GM/GP.TetrameranalysisandIFN-ICSwasperformedon
day 7 postimmunization (mean  SEM; 3 mice per group). (C) Importance of the route of immuniza-
tion. B6 mice were immunized with 105 PFU MHV-GM/GP. Tetramer analysis and IFN- ICS were
performed on day 7 postimmunization (mean  SEM; 2 to 6 mice per group, pooled from 2 different
experiments).(D)Durationofvector-inducedCD8Tcellresponse.B6micewereimmunizedwith105
PFU MHV-GM/GP or MHV-GP. Tetramer analysis and IFN- ICS were performed at the indicated
timepoints(meanSEM;3micepergroup).(E)InvivorestimulationofMHVvector-inducedCD8
memoryTcells.B6micewereimmunizedwith105PFUMHV-GM/GPorinjectedwithPBS.Micewere
boosted on day 65 i.v. with 106 PFU MHV-GM/GP or injected with PBS. Tetramer analysis and IFN-
ICS were performed on day 4 after the booster immunization (mean  SEM; 4 mice per group). i.n.,
intranasal.
Cervantes-Barragan et al.
4 mbio.asm.org September/October 2010 Volume 1 Issue 4 e00171-10tein(MHV-GM/GP),wasthemaximalimmuneresponseinduced
(Fig. S4B). Furthermore, MHV-GM/GP-induced GM-CSF ex-
pression did not alter the cellular composition in spleens (see
Fig. S5 in the supplemental material). These results support the
notion that vector-encoded GM-CSF acts locally in the microen-
vironmentoftransducedDCs.However,invivotransductionwith
both MHV-GP and MHV-GM/GP mediated DC maturation,
with upregulation of CD86 and CD40 (Fig. 2C). Notably, appli-
cation of MHV-GP vectors led to a less efﬁcient transduction of
DCs in vivo, which lasted only for roughly 18 h (Fig. 2A), suggest-
ing that GM-CSF supplied by MHV vectors fosters DC survival
and, to a lesser extent, DC maturation and thereby potentiates
their antigen presentation function.
Antiviral CTL responses following coronavirus vector im-
munization. Infection with LCMV is characterized by a vigorous
expansion of antiviral CTL and persistence of protective memory
CTL (38), which are directed against several epitopes. Two differ-
entepitopesarepresentinthegp33-41regionoftheLCMVGPthat
wasusedintwoofourconstructs:theH2-Db-bindinggp33-41(39)
and the H2-Kb-binding gp34-41 (40). On day 7 after LCMV infec-
tion, signiﬁcant numbers of CD8 T cells could be detected by
MHC tetramer analysis and intracellular cytokine secretion (ICS)
assay (Fig. 3A). It is important to note that the gp33 ICS records
both gp33- and gp34-speciﬁc CD8 T cells. It appears that the
processingoftheGP-EGFPtransgeneintheMHV-GPandMHV-
GM/GP vectors permitted the preferential generation of gp34-
speciﬁc CD8 T cells to a magnitude comparable to that seen
during acute LCMV infection (Fig. 3A). The GM-CSF-encoding
MHV vector proved to be highly efﬁcient in the induction of an-
tiviralCTL,evenatratherlowdosesof103and104PFU(Fig.3B).
Since the intermediate dose of 105 PFU of MHV-GM/GP led to
optimal induction of gp34-speciﬁc CTL, we used this dose to as-
sess whether application via different routes would inﬂuence the
induction of transgene-speciﬁc CTL. As shown in Fig. 3C, all
routes of immunization elicited robust CD8 T cell responses,
with intraperitoneal (i.p.), subcutaneous (s.c.), intramuscular
(i.m.), and i.v. injection being the most efﬁcient means of appli-
cation.BothMHV-GP-andMHV-GM/GP-inducedCD8Tcells
displayed full effector function because gp34 peptide-loaded tar-
getcellswererapidlyeliminatedinimmunizedhosts(seeFig.S6A
in the supplemental material). MHV vector-induced CD8 T cell
responses were detectable for more than 65 days after immuniza-
tion (Fig. 3D) and, most importantly, could be restimulated in
vivo by immunization with the same vector (Fig. 3E).
ProtectionagainstLCMVchallengerequireshighlevelsofappro-
priately activated CD8T cells (38). In order to assess the efﬁcacy of
MHV vector-based immunization for protection against viral chal-
lenge, B6 mice were immunized with graded doses of the MHV-GP
or MHV-GM/GP vector and challenged 7 days later with LCMV.
ComparabletothehighlevelofCD8Tcellinduction(Fig.3),com-
pleteprotectionwasobservedinmiceafterimmunizationwithadose
of 105 PFU (Fig. 4A). Remarkably, as few as 103 PFU of MHV-
GM/GP still led to a 3-log reduction of LCMV titers in spleens on
day 4 postchallenge (Fig. 4A). Protection against LCMV was long-
lasting because mice were still protected after more than 2 months
following immunization with 105 PFU MHV-GM/GP via the i.v.
(Fig. 4B), s.c., or i.m. route (see Fig. S6B in the supplemental mate-
rial).Moreover,theMHV-GM/GPvaccineelicitedcompleteprotec-
tionagainsti.p.challengewithLCMVGPrecombinantvacciniavirus
(VV) (Fig. 4C). Likewise, immunization with MHV-GP provided
substantial protection against this heterologous viral infection
(Fig. 4C). It is important to indicate that the MHV-based vaccine,
even when GM-CSF was encoded by the vector, provided speciﬁc
protectionbecausereplicationoftheunrelatedrecombinantvaccinia
virus expressing vesicular stomatitis virus (VSV) Indiana glycopro-
tein (VV-INDG) was not affected (Fig. 4C). Taken together, these
results revealed that the MHV-based vector system is highly efﬁcient
in generating protective antiviral immunity and that the incorpora-
tion of GM-CSF into the vaccine signiﬁcantly augmented its protec-
tive capacity.
Prophylactic and therapeutic antitumor immunization. In
order to evaluate whether MHV vector-based vaccination elic-
its prophylactic and therapeutic tumor immunity, we resorted
to a rapidly growing B16 melanoma model which provides
compatibilitywiththeLCMVGPsystemthroughexpressionof
a gp33 minigene (B16F10-GP cells) (41). I.v. injection of 5 
105 B16F10-GP or parental B16F10 cells in control B6 mice
resulted in metastatic growth of tumor cells in lungs (Fig. 5A).
Immunization with either 105 PFU MHV-GP or 105 PFU
MHV-GM/GP completely blocked the growth of B16F10-GP
tumor cells, whereas metastasis formation of the parental
B16F10 cells was not affected (Fig. 5A). Application of graded
doses of MHV-GP or MHV-GM/GP revealed the high efﬁcacy
of this vaccination approach in the prophylactic setting, i.e.,
104 MHV-GPoronly103 PFUMHV-GM/GPweresufﬁcientto
prevent the growth of the melanoma cells (Fig. 5B). A long-
lasting memory response that provided signiﬁcant protection
against B16F10-GP challenge had been generated following
MHV-GM/GP immunization (Fig. 5C). Moreover, the potent
CD8 TcellresponseelicitedthroughMHV-GM/GPimmuni-
zation mediated therapeutic tumor immunity (Fig. 5D), i.e.,
thetumorburdeninlungsofB6micewassigniﬁcantlyreduced
evenwhenthevaccinewasappliedafterthetumorshadstarted
to form metastatic nodules, indicating that CD8 T cell re-
FIG 4 Induction of long-lasting protective antiviral immunity. (A) B6 mice
wereeitherleftuntreated(Ctrl)orimmunized(i.v.)withtheindicateddosesof
MHV-GP or MHV-GM/GP. Seven days later, mice were challenged i.v. with
200PFULCMV.Viraltitersinspleens(meansSEM)weredetermined4days
after LCMV challenge using a focus-forming assay on MC57 cells (4 to 6 mice
per group, pooled from 2 different experiments). (B) Duration of protective
antiviral immunity. B6 mice were immunized with 105 PFU MHV-GM/GP
and challenged i.v. with 200 PFU LCMV at the indicated time points. Viral
titersinspleens(meanSEM)weredetermined4daysafterLCMVchallenge
usingafocus-formingassayofMC57cells(4to6micepergroup,pooledfrom
2 different experiments). (C) Female B6 mice were either left untreated (Ctrl)
or immunized (i.v.) with 105 PFU MHV-GP or 105 PFU MHV-GM/GP.
Seven days later, mice were challenged i.p. with 2  106 PFU LCMV GP-
recombinant vaccinia virus (VV-G2) or vesicular stomatitis virus
glycoprotein-recombinant vaccinia virus (VV-INDG). Vaccinia virus titers
(mean  SEM) in ovaries were determined 5 days after challenge infection (4
mice per group). ND, not detectable.
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antitumor activity.
To further substantiate the ﬁnding that MHV vectors can induce
potent and relevant antitumor CD8 T cell responses, we employed
the human HLA-A2-restricted Melan-A/MART1 system, in which
immune responses against the Mel-A26-35 analog peptide can be
monitored in HLA-A2.1-transgenic (A2DR1) mice (42). A2DR1
mice were immunized i.v. with either 105 PFU MHV–Mel-A or 105
PFU MHV-GM/Mel-A, and Mel-A-speciﬁc CD8 T cell responses
were recorded using tetramer analysis and ICS. As shown in Fig. 6A,
both vectors elicited substantial CD8T cell responses. Time course
experiments following i.v. application of MHV-GM/Mel-A revealed
a strong global expansion of CD8 T cells (nearly 10-fold) and a
massiveexpansionofMel-A-speciﬁcCD8Tcells,with2106cells
perspleenbeingtetramerpositiveand6106cellsperspleensecret-
inggammainterferon(IFN-)(Fig.6B).TheMel-A-speciﬁcCD8T
cell population showed a typical contraction after day 7, and a stable
memory population had been established
by day 28 postimmunization (Fig. 6B).
During the acute phase following MHV-
GM/GP immunization, 90% of the Mel-
A-speciﬁcCD8Tcellshaddownregulated
CD62L (Fig. 6C). As expected, memory
CD8 T cells reacquired CD62L expres-
sion, indicating establishment of a central
memory CD8 T cell population. Overall,
these results underline that the
coronavirus-based vaccination approach,
particularly in combination with the im-
munostimulatory cytokine GM-CSF, pro-
vides efﬁcient means for the induction of
CD8Tcellresponsesagainstahumantu-
mor antigen.
Delivery of tumor antigen to human
DCs. Human coronavirus-based vectors
permit speciﬁc transfer of multiple genes
to DCs because the receptor of HCoV-
229E, human aminopeptidase N (hAPN
or CD13) (43), is expressed on human
DCs (31). Furthermore, we have demon-
strated previously that HCoV-229E-
based vectors can transduce immature
and mature human DCs with reporter
genes such as the ﬁreﬂy luciferase gene
(30). Here we assessed whether HCoV-
229E-mediateddeliveryoftheMel-A26-35
analog peptide to HLA-A2 human DCs
would speciﬁcally stimulate human Mel-
A-speciﬁc CD8 T cells. To this end, we
generated two recombinant human
coronaviruses, designated HCoV–
Mel-A and HCoV–GP-EGFP, through
replacement of HCoV-229E accessory
gene4withthegenefortheEGFP–Mel-
A26-35orgp33-EGFPfusionprotein,re-
spectively (Fig. 7A). As shown in
Fig. 7B, EGFP expression was readily
detectable in both human immature
andmatureDCsafterHCoV–Mel-Ain-
fection. Time course analysis of human
mature DCs infected with HCoV–Mel-A or HCoV–GP-EGFP
revealed that high levels of EGFP expression can be reached as
early as 9 h postinfection (see Fig. S7 in the supplemental mate-
rial). Finally, mature DCs infected with HCoV–Mel-A or HCoV–
GP-EGFPwereemployedtostimulateMel-A26-35-speciﬁchuman
T cells. As shown in Fig. 7C, we observed efﬁcient stimulation of
the tumor-speciﬁc T cells by HCoV–Mel-A, indicating that
HCoV-229E, with its pronounced tropism for human CD13-
expressing DCs, represents a particularly promising tool for ge-
netically delivering antigens to human antigen-presenting cells.
DISCUSSION
This study describes a novel vaccine approach that facilitates de-
livery of viral or tumor antigens to DCs in vivo. Concomitant
immunostimulation—here via the cytokine GM-CSF—was
achieved through targeted transduction by the same viral vector.
Single immunization with only 104 to 105 MHV-based particles
FIG5 Preventionandimmunotherapeutictreatmentofmetastaticmelanoma.(A)B6micewereeither
left untreated (Ctrl) or immunized (i.v.) with either 105 PFU MHV-GP or MHV-GM/GP. Seven days
later, mice were challenged with 5  105 LCMV gp33-recombinant B16F10-GP tumor cells or parental
B16F10 tumors cells i.v. Tumor growth in lungs was recorded on day 12 after tumor challenge. Macro-
scopic pictures show representative lungs from 1 out of 3 mice per group. (B) Efﬁcacy of MHV-based
vectors in generating prophylactic tumor immunity. B6 mice were immunized i.v. with the indicated
doses of MHV-GP or MHV-GM/GP or infected i.v. with 200 PFU LCMV and challenged as described
forpanelA,andnumbersofmetastaticfociperlungweredeterminedonday12(meansSEM;6mice
pergroup,pooledfrom2experiments).(C)Durationofprotectiveantitumorimmunity.B6micewere
immunizedi.v.with105PFUMHV-GM/GP,infectedi.v.with200PFULCMV,orleftuntreated(Ctrl).
Mice were challenged as described for panel A, and tumor growth was determined on day (d) 12
postchallenge (means  SEM; 4 to 6 mice per group, pooled from 2 experiments). (D) Therapeutic
antitumor immunity. B6 mice received 5  105 LCMV gp33-recombinant B16F10-GP tumor cells i.v.
andwereimmunizedwith105PFUMHV-GM/GPi.v.eitheronthesameday(day0)or4or8dayslater.
Photographsofdorsalandventralsidesofaffectedlungsaredisplayed.Diseaseseveritywasdetermined
on day 20 after tumor inoculation; data indicate affected lung surfaces as determined by black pixel
counting(meanSEM;4micepergroup).StatisticalanalysiswasperformedusingStudent’sttest(***,
P  0.001; **, P  0.01; *, P  0.05; a P value of 0.05 was not signiﬁcant). ND, not detectable.
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entiationofCD8Tcells,(ii)protectiveandlong-lastingantiviral
immunity, and (iii) prophylactic and therapeutic tumor immu-
nity. Moreover, highly efﬁcient antigen delivery to human DCs
withrecombinantHCoV-229Eandspeciﬁcstimulationofhuman
CD8 T cells revealed that this approach is exceptionally well
suited for translation into human vaccine studies.
Targeting of antigen to DCs in vivo can be achieved by several
means(5).Theuseofviralvectorsappearstobethesuperiorstrategy
for eliciting innate activation of the immune system and optimal in-
duction of CD8 T cells (24). However, many virus vector systems
are still limited in their ability to induce broad and long-lasting im-
mune responses. For example, recombinant adenoviruses have been
studied intensively as vaccine candidates mainly because they can be
producedtohightiters.Nevertheless,highdosesofrecombinantad-
enovirus vectors have to be applied to in-
duce an immune response, most probably
becausetheytargetantigensmainlytonon-
lymphoid organs, such as the liver (25, 44).
In contrast to viral vectors based on DNA
viruses (45), positive-stranded RNA virus-
based vectors that replicate in the cyto-
plasm are considered safe vectors. The
safety is well documented for vectors based
on widely used vaccine strains, such as po-
liovirus (46), or virus-like particles (VLPs)
thatcontainrepliconRNAsdevoidofstruc-
turalgenes(47).Itshouldbenotedthatap-
plication of the MHV-based vectors de-
scribed in this study was always well
tolerated and did not result in any sign of
disease or adverse side effect irrespectively
of dosage and route of MHV-based vector
application, even in immunodeﬁcient
mousestrains.Finally,itisnoteworthythat
although some RNA virus-based vectors
are able to target DCs (21), their cloning
capacity is, in sharp contrast to that of
coronavirus-based vectors, generally re-
stricted and the expression of multiple an-
tigens and/or immunostimulatory cyto-
kines is limited.
The novel coronavirus-based vaccine
platform described here displayed a high
immunogenicity. It is very likely that it is
the pronounced tropism of the MHV-
based vectors for DCs and macrophages
within secondary lymphoid organs that
guarantees efﬁcient activation of primary
CD8 T cell responses. In vivo imaging
studies have shown that CD169
CD11c DCs at the subcapsular sinus of
lymph nodes efﬁciently present viral an-
tigen to naïve T cells (48). Likewise,
CD169 macrophages at the same loca-
tion are able to collect viral antigen from
the lymph and present antigen to follicu-
lar B cells (49). Moreover, a recent study
from our laboratory has revealed that
type I IFN-mediated protection of DCs
and macrophages from cytopathic effects of MHV infection is
essential to buy time for mounting a protective CD8 T cell re-
sponse (50). It remains to be resolved which factors—besides the
presence of the MHV receptor on DCs (32)—confers the prefer-
entialinfectionoftherelevantantigen-presentingcellswithinsec-
ondary lymphoid organs. For further adaptation of the
coronavirus-based vectors to the human system, some of the es-
sential parameters have been clariﬁed; i.e., the receptor of HCoV-
229E is expressed mainly on monocytes and DCs within second-
ary lymphoid organs (31), and recombinant HCoV-229E
efﬁcientlytargetshumanDCsirrespectiveoftheirmaturationsta-
tus. It is important to add that HCoV-229E is one of at least four
human coronaviruses that are transmitted via mucosal surfaces
and are associated with mild upper respiratory tract infections
(common cold). Furthermore, the low pathogenic potential of
FIG 6 Assessment of anti-Melan-A/MART1 CD8 T cells in A2DR1 mice. (A) Transgenic mice
expressing the human HLA-A2.1 molecule were immunized i.v. with 105 PFU MHV–Mel-A or MHV-
GM/Mel-A.Atday7postinfection,splenocytesandmononuclearbloodcellswereanalyzedforexpres-
sion of CD8 and reactivity with HLA-A2/Mel-A26-35 tetramers and for Mel-A26-35-speciﬁc IFN- and
TNF- production. Values in the upper right quadrants represent mean percentages of Tet cells 
SEM in blood and spleen, percentages of IFN- cells  SEM, or percentages of TNF- cells  SEM
in the CD8 T-cell compartment (3 mice per group). (B) Time course of Mel-A26-35-speciﬁc CD8
T-cell responses in A2DR1 mice following i.v. immunization with 105 PFU MHV-GM/Mel-A. Total
numbers of CD8 T cells, tetramer-binding Mel-A26-35-speciﬁc CD8 T cells, and Mel-A26-35-speciﬁc
IFN-CD8Tcellsweredeterminedattheindicatedtimepointspostimmunization(meansSEM;
3 mice per group). (C) Differentiation of tetramer-binding Mel-A26-35-speciﬁc CD8 T-cells as deter-
minedbyCD62Lexpressionattheindicatedtimepointspostimmunization(meansSEM;3miceper
group). Data are from one representative experiment out of three. hi, high-level expression.
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saged in volunteers in the 1960s without any serious side effects.
Thesefeatures,togetherwiththepronouncedDC-targetingcapa-
bilities demonstrated in this report, should encourage the devel-
opment of coronavirus-based vectors for human use.
A second major advantage of the coronavirus-based vaccina-
tion strategy is the large cloning capacity of the vectors, which
offers the possibility of incorporating immunostimulatory cyto-
kines. GM-CSF-encoding MHV vectors led to strong production
of this cytokine in both macrophages and DCs in vitro. Interest-
ingly,GM-CSFexpressioninvivoappearedtobelargelyrestricted
to locally transduced cells, as no gross differences in GM-CSF
levelsinspleenorserumwereobservedafterMHV-GM/GPvector
immunization. It is most likely that GM-CSF-induced changes
within the microenvironment of transduced macrophages and
DCsaredecisivefortheoptimalinductionofeffectorandmemory
CD8 T cell responses. Indeed, it is the optimally stimulated ex-
pression of costimulatory molecules on antigen-presenting cells,
together with sufﬁcient innate immune stimulation, that deter-
mines the primary expansion and the maintenance of antiviral
CD8Tcells(51).Accordingly,suchnon-TCRsignals(“signals2
and 3”) are considered key components of rationally designed
vaccines (4). The lack of such optimally composed stimuli in a
vector-based vaccine most likely requires very elaborate prime-
boost immunization regimes, as was recently shown for a com-
bined adenovirus/MVA vaccination approach (52), and/or sub-
stantiallyincreasedvectordosestoachieveefﬁcacy,asforexample
in vaccination with the latest versions of DC-adapted lentivirus
vectors, where application of 5  107 to 10  107 particles was
required to achieve signiﬁcant expansion of ovalbumin-speciﬁc
CD8 T cells in mice (53).
In conclusion, we provide here a versatile vaccine platform
based on coronaviruses that achieved the efﬁcient generation of
protective immunity, shown as long-lasting memory against viral
challenge and induction of both prophylactic and therapeutic tu-
mor immunity. The biology of coronaviruses and the rational
modiﬁcation of these viral RNA vectors harbor signiﬁcant poten-
tial for future development.
MATERIALS AND METHODS
Ethics statement. Experiments were performed in accordance with fed-
eral and kantonal guidelines under permission numbers SG07/62, SG07/
63, 07/64, and 07/71 following review and approval by the Kantonal Vet-
erinary Ofﬁce (St. Gallen, Switzerland).
Mice, cells, and viruses. C57BL/6 mice were obtained from Charles
River Laboratories (Sulzfeld, Germany). A2DR1 mice were kindly sup-
plied by F. A. Lemonnier (Pasteur Institute, Paris, France) (42). All mice
weremaintainedinindividuallyventilatedcagesandwereusedatbetween
6 and 9 weeks of age. L929 and CV-1 cells were purchased from the Eu-
ropean Collection of Cell Cultures. MC57 and BSC40 cells were obtained
from R. M. Zinkernagel (University of Zürich, Switzerland). D980R cells
were a kind gift from J. F. Smith (Imperial College London, London,
United Kingdom). 17clone1 cells were a kind gift from S. G. Sawicki
(Medical University of Ohio, Toledo, OH). Huh7 cells were a kind gift
from V. Lohmann (University of Heidelberg, Germany). The LCMV WE
strainwasobtainedfromR.M.Zinkernagel(UniversitätZürich,Switzer-
land).RecombinantvacciniavirusexpressingLCMVglycoprotein2(VV-
G2) was originally obtained from B. H. Bishop (University of Oxford,
United Kingdom), and recombinant vaccinia virus expressing vesicular
stomatitisvirusIndianaglycoprotein(VV-INDG)wasoriginallyobtained
from B. Moss (National Institutes of Health, Bethesda, MD). Titration
and determination of antiviral protection assays have been performed as
described previously (7). Further details can be found in Text S1 in the
supplemental material.
Cloning and generation of recombinant MHV-based vectors and
human coronaviruses. Genomic RNA of recombinant MHV-based vec-
tors and recombinant HCoVs were produced from cloned cDNA using
puriﬁed vaccinia virus DNA as the template for in vitro transcription as
described previously (54). A detailed description of all cloning steps, se-
quence information, and production of recombinant coronavirus parti-
cles can be found in Text S1 in the supplemental material.
Isolation of dendritic cells and macrophages, ﬂow cytometry, im-
munoﬂuorescence. Generation of bone marrow-derived DCs and ﬂow cy-
tometricanalysiswereperformedasdescribedpreviously(50).Furtherinfor-
mation on these procedures can be found in Text S1 in the supplemental
material.Forimmunoﬂuorescenceanalysisofviralreplication,2105L929
cells or peritoneal macrophages were seeded in slide chambers and trans-
FIG 7 Transduction of human DCs with Melan-A-recombinant HCoV-
229E. (A) Schematic representation of the modiﬁed HCoV-229E viruses en-
coding different antigen cassettes. (B) Human monocyte-derived DCs, either
immatureormature,wereinfectedwithrecombinantHCoV-229E(MOI1)
encoding the EGFP–Mel-A26-35 fusion protein. Cells were harvested 12 h later
and stained for the indicated surface molecules. (Left) Maturation status as
assessed by CD14 and CD86 costaining. Values in the lower right panels indi-
cate percentages of CD14 CD86 cells. (Right) Transduction efﬁcacy mea-
suredasEGFPexpression.Valuesintheupperrightpanelindicatepercentages
of CD13 EGFP cells. The results of one representative experiment out of 4,
with DCs derived from different donors, are shown. (C) Activation of a Mel-
A-speciﬁcTcellclonebyMel-A26-35-presentingDCs.MatureDCswereeither
leftuntreated,pulsedwiththeMel-A26-35peptide,transducedwithGP-EGFP-
recombinant HCoV-229E, or transduced with EGFP–Mel-A26-35-
recombinantHCoV-229E(MOI1).DCsandTcellswerecoculturedfor6h
ata4:1ratio,andactivationoftheTcellswasassessedbyIFN-ICS.Valuesin
the histogram indicate percentages of IFN--expressing T cells. The results of
one representative experiment out of three are shown.
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cated in Fig. 1, the slides were acetone ﬁxed, blocked with the Fc-blocking
antibody 2.4G2, and stained with anti-EGFP Alexa 488 (BioLegend). Images
were acquired using a Leica DMRA microscope and processed using Adobe
Photoshop (Adobe Systems).
Tetramer analysis and intracellular cytokine staining. Peptide-
speciﬁc CD8 T cells and ex vivo production of IFN- or tumor necrosis
factoralpha(TNF-)weredeterminedbytetramerstaining,andintracel-
lular cytokine staining was performed as described previously (24, 28).
Detailed information on these procedures can be found in Text S1 in the
supplemental material.
Melanoma model. B16F10-GP melanoma cells expressing the LCMV
gp33 epitope (41) and parental B16F10 cells were kindly provided by H.
Pircher (University of Freiburg, Germany). Further information on tumor
protection assays can be found in Text S1 in the supplemental material.
GenerationofhumanDCsandICS.DCsweregeneratedfrommono-
cytes isolated from peripheral blood mononuclear cells as described pre-
viously (55). Mature DCs were infected with Mel-A/EGFP-recombinant
HCoV-229E or GP-EGFP-recombinant HCoV-229E and incubated with
Mel-A-speciﬁc T cell clones as responder cells. Further details on in vitro
humanCD8TcellactivationbytransducedhumanDCscanbefoundin
Text S1 in the supplemental material.
Statisticalanalysis.AllstatisticalanalyseswereperformedwithPrism
4.0 (GraphPad Software Inc.). Data were analyzed with the nonpaired
Student t test under the assumption that the values followed a Gaussian
distribution. A P value of 0.05 was considered signiﬁcant.
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